Targets › GSS
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Sep 2027.
Catalyzes the production of glutathione from gamma-glutamylcysteine and glycine in an ATP-dependent manner. Glutathione (gamma-glutamylcysteinylglycine, GSH) is the most abundant intracellular thiol in living aerobic cells and is required for numerous processes including the protection of cells against oxidative damage, amino acid transport, the detoxification of foreign compounds, the maintenance of protein…. (UniProt, P48637)
Open in Phaseline: the race on GSS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gateway Institute for Brain Research | INS-GSH Intranasal insulin and glutathione combination | INS, GSS | Phase 2 | Parkinson Disease | Sep 2027 |
Parkinson Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.